Logo

Precision BioSciences Receives the US FDA's Fast Track Designation for PBCAR0191 to Treat Advanced B-cell Precursor Acute Lymphoblastic Leukemia

Share this

Precision BioSciences Receives the US FDA's Fast Track Designation for PBCAR0191 to Treat Advanced B-cell Precursor Acute Lymphoblastic Leukemia

Shots:

  • The US FDA has granted FT designation for PBCAR0191 to treat advanced B-ALL. FT designation facilitates the expedited development and review of a new drug- whether alone or in combination with another drug addressing the unmet medical needs and treats a serious or life-threatening disease
  • Under the agreement with Servier- Precision will solely lead early-stage research activities and P-I execution for PBCAR0191 along with clinical supply for P-II clinical trials. Servier has an exclusive right to opt in for late-stage development and commercialization while Precision has the right to participate in the process of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the US
  • PBCAR0191 is an allogenic CART cell therapy- currently being evaluated in a P-I/IIa study evaluating PBCAR0191 in adult patients with r/r B-ALL and r/r NHL

­ Ref: Precision BioSciences | Image: StraitTimes

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions